P3HR-1Homo sapiens (Human)Cancer cell line
Also known as: P 3 HR 1, P3HR1, P3HRI, P3HR1-BL, P3J HR-1, P3J-HR-1, P3JHR-1, P3JHR1, P3JHRI, P3J HR1-K, P3J.HR1K, HR-1, HR1, HRI, HR1K, PO, HAI
Quick Overview
P3HR-1 is a human B-cell lymphoma cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_2676 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ascites[UBERON:UBERON_0007795] |
Donor Information
| Age | 7 |
|---|---|
| Age Category | Pediatric |
| Sex | Male |
| Race | black_or_african_american |
Disease Information
| Disease | EBV-related Burkitt lymphoma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Burkitt Lymphoma |
| OncoTree Code | BL |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000707_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | MYC | p.Pro72Ser (c.214C>T) | Unspecified | - | PubMed=8108117 |
| MutationSimple | NRAS | p.Gln61Lys (c.181C>A) | Unspecified | Acquired during resistance selection process | PubMed=26214590 |
| MutationSimple | TP53 | p.Tyr163His (c.487T>C) | Unspecified | - | from parent cell line P3HR-1 |
| MutationSimple | TP53 | p.Glu287Ter (c.859G>T) | Unspecified | - | from parent cell line P3HR-1 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
J. Virol. 89:713-729(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Int. J. Cancer 125:212-221(2009).
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Maesako Y., Uchiyama T., Ohno H.
Cancer Sci. 94:774-781(2003).
Enhanced destruction of lymphoid cell lines by peripheral blood leukocytes taken from patients with acute infectious mononucleosis.
Hutt L.M., Huang Y.-T., Dascomb H.E., Pagano J.S.
J. Immunol. 115:243-248(1975).
Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.
Adams A., Strander H., Cantell K.
J. Gen. Virol. 28:207-217(1975).
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
Fogh J., Fogh J.M., Orfeo T.
J. Natl. Cancer Inst. 59:221-226(1977).
Comparative study on radiosensitivities of cultured cell lines derived from several human tumors under hypoxic condition.
Inada T., Kasuga T., Nojiri I., Hiraoka T., Furuse T.
Gann 68:357-362(1977).
p53 is frequently mutated in Burkitt's lymphoma cell lines.";
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
EMBO J. 10:2879-2887(1991).
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Nakano A., Harada T., Morikawa S., Kato Y.
Acta Pathol. Jpn. 40:107-115(1990).
The chromosomes of the EB virus-positive Burkitt cell line P3J.HR1K studied by the fluorescent staining technique.
Petit P., Verhest A., Lecluse-van der Bilt F.A., Jongsma A.P.M.
Pathol. Eur. 7:17-21(1972).
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.
Klein G., Dombos L., Gothoskar B.
Int. J. Cancer 10:44-57(1972).
Studies on the infectivity and cytopathology of Epstein-Barr virus in human lymphoblastoid cells.
Durr F.E., Monroe J.H., Schmitter R., Traul K.A., Hirshaut Y.
Int. J. Cancer 6:436-449(1970).
Incidence of EB virus-containing cells in primary and secondary clones of several Burkitt lymphoma cell lines.
Maurer B.A., Imamura T., Wilbert S.M.
Cancer Res. 30:2870-2875(1970).
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.
Klein G., Dombos L.
Int. J. Cancer 11:327-337(1973).
Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.
Grace J.T. Jr.
J. Virol. 1:1045-1051(1967).
The action of DNA antagonists on Epstein-Barr virus (EBV)-associated early antigen (EA) in Burkitt lymphoma lines.
Gergely L., Klein G., Ernberg I.
Int. J. Cancer 7:293-302(1971).
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Ehlin-Henriksson B., Klein G.
Int. J. Cancer 33:459-463(1984).
Examination of Epstein-Barr virus and C-type proviral sequences in American and African lymphomas and derivative cell lines.
Sherrick D., Gray T.E.
Cancer Res. 41:3165-3171(1981).
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. I. Isolation, characterization, cell surface markers, and B-cell markers.
Terasaki P.I., Ralph P.
J. Natl. Cancer Inst. 68:179-195(1982).
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II. Epstein-Barr virus induction patterns.
Klein G., Zeuthen J., Ber R., Ernberg I.
J. Natl. Cancer Inst. 68:197-202(1982).
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
Parsons R.G.
J. Immunol. 129:1336-1342(1982).
Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
Trach L.
J. Natl. Cancer Inst. 69:585-590(1982).
Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T., Urlbauer B., Kohlhuber F., Hammersen B., Eick D.
Oncogene 9:759-763(1994).
Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Bhatia K.G., Huppi K., Spangler G., Siwarski D., Iyer R., Magrath I.T.
Nat. Genet. 5:56-61(1993).
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
Magrath I.T.
FASEB J. 7:951-956(1993).
Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.
Kohn K.W.
Cancer Res. 53:4776-4780(1993).